FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A new dawn for tovorafenib
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
